Evaluation value of Rades score on radiotherapy-related survival prognosis in patients with metastatic spinal cord compression / 中国医师进修杂志

ABSTRACT

Objective:To evaluate the radiotherapy-related survival prognosis value of Rades score in patients with metastatic spinal cord compression (MSCC).Methods:The clinical data of 110 patients with MSCC who underwent radiotherapy from January 2010 to January 2014 in Cancer Hospital of the University of Chinese Academy of Sciences were retrospectively analyzed. The primary tumor was 36 cases of prostate cancer, 18 cases of myeloma/lymphoma, 15 cases of breast cancer, 7 cases of lung cancer, and 34 cases of other types of cancer. The survival status, overall survival time and Rades score were recorded. The influencing factors of survival prognosis and the relationship between the Rades score and survival prognosis were analyzed.Results:The 84.5% (93/110) patients had a radiotherapy dose of 20 Gy/5 times; 5.5% (6/110) patients (operated patients or myeloma/lymphoma patients) had a radiotherapy dose of 30 Gy/10 times. Thirty-seven cases were treated by surgery. The patients were followed up for (38.6 ± 15.2) months, and the overall survival period was (15.2 ± 0.5) months. Cox proportional hazards model analysis result showed that the primary tumor type, surgical treatment, combined chemotherapy and Rades score were the risk factors of survival prognosis in patients with MSCC ( P<0.05). Among the 110 patients, Rades score was 20 to 30 scores in 17 cases (group A), 31 to 35 scores in 40 cases (group B), and 36 to 45 scores in 53 cases (group C). The 6-month survival rate in group C was significantly higher than that in groups A and group B 45.3% (24/53) vs. 0 and 27.5% (11/40), and there was statistical difference ( P<0.05). The 5-year survival rate in group C was 22.6% (12/53), and the 5-year survival rates in both groups A and group B were 0. Conclusions:Rades score is related to the survival prognosis of MSCC patients, and can assist in formulating radiotherapy programs for MSCC patients.